Skip to content
Screener

BioMarin Pharmaceuticals BMRN Intangibles (Net)

Intangibles (Net) at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$380.68M+221%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$5.79M-17.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$27.36M-1.6%
XER
Xeris Biopharma Holdings, Inc.XERS
$82.66M-11.6%
Opko Health logo
Opko HealthOPK
$477.57M-14.1%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$35.25M—

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemJune 30,2026December 31,2025
Finite-lived intangible assets$5,173,642$723,966
Indefinite-lived intangible assets300,000—
Gross intangible assets:5,473,642723,966
Accumulated amortization(594,275)(510,129)
Net carrying value$4,879,367$213,837

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's intangibles (net)?
BioMarin Pharmaceuticals (BMRN) reported intangibles (net) of $4.88B in Q2 2026.
How has BioMarin Pharmaceuticals's intangibles (net) changed year-over-year?
BioMarin Pharmaceuticals's intangibles (net) increased by 1936.3% year-over-year, from $239.62M to $4.88B.
What is the long-term trend for BioMarin Pharmaceuticals's intangibles (net)?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's intangibles (net) has grown at a -12.5% compound annual growth rate (CAGR), from $417.27M to $213.84M.
What does intangibles (net) mean?
Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.

Ask your AI about BioMarin Pharmaceuticals's intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude